In:
Haemophilia, Wiley, Vol. 28, No. 4 ( 2022-07), p. 542-547
Abstract:
Nonacog alfa, a standard half‐life recombinant factor IX (FIX), is used as a prophylactic treatment in severe haemophilia B (SHB) patients. Its half‐life determined in clinical studies involving a limited sampling (72 h) was shown to be rather short. In our clinical practice, we suspected that its half‐life could have been underestimated. Objectives We aimed to evaluate nonacog alfa pharmacokinetics in real world clinical practice based on FIX levels in patients receiving prophylaxis. Methods We retrospectively collected data on patients with SHB receiving prophylaxis from eight centres across France. The terminal half‐life (THL), time to reach 5–2 IU/dl and FIX activity at 48, 72 and 96 h were derived by Bayesian estimations using NONMEM analysis. Results and conclusions Infusion data ( n = 455) were collected from 64 patients with SHB. The median THL measured in 92 pharmacokinetic (PK) studies was 43.4 h. In 26 patients ≤12 years of age, 51 PK studies showed a median time to reach 5 IU/dl of FIX of 70.5 h and a median time to reach 2 IU/dl of 121.5 h. In 38 patients 13–75 years of age, 41 PK studies showed a median time to reach 5 IU/dl of FIX of 92.0 h and a median time to reach 2 IU/dl of 167.5 h. Extending the sampling beyond 72 h makes it possible to observe a plateau, with FIX remaining between 2 and 5 IU/dl for several days and shows that the THL of nonacog alfa might be longer than previously described. Essentials Nonacog alfa terminal half‐life (THL) in patients receiving regular prophylaxis was evaluated in clinical practice. The median THL was estimated to be 36.9 h for patients aged .8–12 years. The median THL was estimated to be 49.9 h for patients aged 13–75 years. For patients aged ≤12 and 〉 12 years, the median times to reach 5 IU/dl were 70.5 and 92 h, respectively; to reach 3 IU/dl, 95.5 and 131.5 h, respectively; to reach 2 IU/dl, 121.5 and 167.5 h, respectively. We suggest that the half‐life of nonacog alfa might be longer than previously described in both younger and older patients.
Type of Medium:
Online Resource
ISSN:
1351-8216
,
1365-2516
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2006344-1
